ARESTIN® plus SRP: Comprehensive treatment that goes beyond shrinking pockets

Promotes a healthier oral environment so healing can begin

ARESTIN® interrupts the periodontal disease cascade, inhibiting the progression of the disease.

Hear a Peer Carousel

Periodontitis is an active, persistent infection that requires more than scaling and root planing (SRP).

ARESTIN® (minocycline HCl) is a sustained release, locally applied antibiotic that targets the red complex bacteria underlying the active, persistent infection of periodontal disease.

When you add ARESTIN® (minocycline HCl) to SRP, your patients receive the benefits of comprehensive treatment that's superior to scaling and root planing alone.

  • Decreased bleeding on probing
  • Immediate and sustained reductions in harmful periodontal bacteria to healthier levels
  • A healthier oral environment for up to 30 days, so healing can begin
  • Decreased pocket depth

ARESTIN® (minocycline HCl) is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® (minocycline HCl) may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

ARESTIN® (minocycline HCl) contains minocycline, a tetracycline derivative, and therefore should not be used in children and in pregnant or nursing women. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth.

The most common treatment-emergent adverse events were headache (9.0%), infection (7.6%), flu syndrome (5.0%), and pain (4.3%). These occurred at a similar rate to SRP and SRP + placebo.

Please see accompanying full Prescribing Information.

Download Adobe Reader
Download the free Adobe® Reader® plug-in.

ARESTIN® is indicated as an adjunct to scaling and root planing (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

ARESTIN® should not be used in any patient who has a known sensitivity to minocycline or tetracyclines. The use of drugs of the tetracycline class during tooth development may cause permanent discoloration of the teeth, and therefore should not be used in children or in pregnant or nursing women. Hypersensitivity reactions that included, but were not limited to, anaphylaxis, angioneurotic edema, urticaria, rash, swelling of the face and pruritus have been reported with the use of ARESTIN®. In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome and pain.

Please see Full Prescribing Information

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Contact us with questions about your account or MyArestin.com